Amarin Corp Plc (AMRN)

[DeepBreath]

Bio,

Hope you don't mind, but I changed and resent your template letter to the DOJ

To whom it may concern,

It is clear to many people that John Fuson, a former FDA employee, is collaborating with GlaxoSmithKline (GSK) in an attempt to monopolize the EPA prescription fish oil industry and therefore violating the U.S. Sherman Act.

GSK has a history of this type of behavior (Chemi Spa VS. GSK) and the connection of Mr. Fuson to the FDA and the recent behavior of the FDA towards Amarin Corp. and it's proposed anchor indication needs to be investigated. The citizens petition that Mr. Fuson filed (Lovza Citizens Petition, Feb 2013) was nothing more than an attempt to delay the New Chemical Entity decision by the FDA for Amarin's drug Vascepa. The petition's main goal was to have Vascepa's API listed into the OB retroactively. In August, the FDA failed to rule on the petition, ignoring it's own rules, therefore resulting in a further delay in the NCE decision.

All of these actions have resulted in major financial ruin for the company and it's shareholders. It is important for the American people to know that Big Pharma drug companies cannot use improper legal/administrative actions to secure their monopolies in their respective markets.

This information has been forwarded to the Health and Human Services Office of Inspector General and I have been unable to verify any actions being taken. The American people need to be protected by this type of behavior and the responsibility to enforce this protection falls within the duties of your office. I respectfully ask the DOJ and FTC look into these allegations that may include Criminal Antitrust violations against Amarin Corp, by conspiring to create an unfair restraint of trade